Novocure Ltd (NVCR) Stock Analysis

What Novocure Ltd does

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Key metrics

ETFs linked to NVCR

Broad-market and Healthcare sector ETFs an investor holding Novocure Ltd is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NVCR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Novocure Ltd?

Novocure Ltd trades under the ticker NVCR on NASDAQ.

Which exchange is NVCR listed on?

NVCR is listed on NASDAQ.

What sector does Novocure Ltd operate in?

Novocure Ltd is classified in the Healthcare sector (Medical - Devices industry).

How can PortView help analyze NVCR in a portfolio?

PortView shows NVCR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.